| # | Drug | Count |
|---|---|---|
| 0 | CYCLOPHOSPHAMIDE | 97 |
| 1 | CYCLOPHOSPHAMIDE FOR INJECTION | 97 |
| 2 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 97 |
| 3 | RITUXIMAB | 97 |
| 4 | METHOTREXATE SODIUM | 92 |
| 5 | METHOTREXATE | 83 |
| 6 | PREDNISONE | 83 |
| 7 | DOXORUBICIN | 70 |
| 8 | TACROLIMUS | 59 |
| 9 | TACROLIMUS EXTENDED-RELEASE CAPSULES | 59 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | SILTUXIMAB | 2 | 0.0031 |
| 1 | BARICITINIB | 8 | 0.0026 |
| 2 | POLATUZUMAB VEDOTIN | 26 | 0.0025 |
| 3 | TREOSULFAN | 7 | 0.0025 |
| 4 | MEGNESIUM OXIDE | 1 | 0.0024 |
| 5 | TAFASITAMAB-CXIX | 2 | 0.0022 |
| 6 | GLOFITAMAB | 5 | 0.0018 |
| 7 | RASBURICASE | 4 | 0.0016 |
| 8 | CARMUSTINE | 6 | 0.0013 |
| 9 | SODIUM HYALURONATE | 1 | 0.0012 |
| # | Drug class | Count |
|---|---|---|
| 0 | Corticosteroid [EPC] | 145 |
| 1 | Alkylating Drug [EPC] | 102 |
| 2 | CD20-directed Cytolytic Antibody [EPC] | 97 |
| 3 | Folate Analog Metabolic Inhibitor [EPC] | 83 |
| 4 | Nucleoside Metabolic Inhibitor [EPC] | 41 |
| 5 | Platinum-based Drug [EPC] | 41 |
| 6 | Topoisomerase Inhibitor [EPC] | 36 |
| 7 | Tumor Necrosis Factor Blocker [EPC] | 33 |
| 8 | Purine Antimetabolite [EPC] | 30 |
| 9 | Calcineurin Inhibitor Immunosuppressant [EPC] | 27 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Interleukin-6 Antagonist [EPC] | 2 | 0.0031 |
| 1 | Interleukin-5 Antagonist [EPC] | 1 | 0.0015 |
| 2 | Bispecific CD20-directed CD3 T Cell Engager [EPC] | 5 | 0.0012 |
| 3 | CD19-directed Chimeric Antigen Receptor [EPC] | 12 | 0.0012 |
| 4 | Nuclear Export Inhibitor [EPC] | 5 | 0.0006 |
| 5 | Type I Interferon Receptor Antagonist [EPC] | 1 | 0.0005 |
| 6 | Topoisomerase Inhibitor [EPC] | 36 | 0.0005 |
| 7 | CCR5 Co-receptor Antagonist [EPC] | 1 | 0.0004 |
| 8 | Alkylating Drug [EPC] | 102 | 0.0004 |
| 9 | CD30-directed Immunoconjugate [EPC] | 4 | 0.0004 |